Renal denervation suppresses the inducibility of atrial fibrillation in a rabbit model for atrial fibrosis

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Wei, Yong ^a,b   Xu, Juan ^b   Zhou, Genqing ^b   Chen, Songwen ^b   Ouyang, Ping ^a   Liu, Shaowen ^b  

^a Songjiang People Hospital of Shanghai   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; CHYMOSIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA CONSTRICTION; ARTICLE; ATRIAL FIBRILLATION; BLOOD VESSEL DIAMETER; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEART ATRIUM REMODELING; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBROSIS; HEART PACING; INCIDENCE; INTRACELLULAR SPACE; KIDNEY DENERVATION; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STAINING; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; DENERVATION; DISEASE MODEL; GENE EXPRESSION REGULATION; HEART ATRIUM; INNERVATION; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; RABBITS AND HARES;

ALDOSTERONE; ANIMALS; ATRIAL FIBRILLATION; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DENERVATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEART ATRIA; KIDNEY; MALE; RABBITS; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84984607941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160634     Document Type: Article

References (29)

1. de Vos CB, Nieuwlaat R, Crijns HJ, Camm AJ, LeHeuzey JY, Kirchhof CJ, et al. Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J. 2008; 29: 632-639. doi: 10.1093/eurheartj/ehn025 PMID: 18270212
2. Ogawa M, Zhou S, Tan AY, Song J, Gholmieh G, Fishbein MC, et al. Left stellate anglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol. 2007; 50: 335-343. PMID: 17659201
3. Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008; 118: 916-925. doi: 10.1161/CIRCULATIONAHA.108.776203 PMID: 18697820
4. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012; 60:1163-1170. doi: 10.1016/j.jacc.2012.05.036 PMID: 22958958
5. Zhao Q, Yu S, Zou M, Dai Z, Wang X, Xiao J, et al. Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. Interv Card Electrophysiol. 2012; 35: 119-125.
6. Wang X, Zhao Q, Huang H, Tang Y, Xiao J, Dai Z, et al. Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing. PLoS One. 2013; 8: e64611. doi: 10.1371/journal.pone.0064611 PMID: 23724069
7. Takahashi N, Kume O, Wakisaka O, Fukunaga N, Teshima Y, Hara M, et al. Novel strategy to prevent atrial fibrosis and fibrillation. Circ J. 2012; 76: 2318-2326. PMID: 22972366
8. Dias LD, Casali KR, Leguisamo NM, Azambuja F, Souza MS, Okamoto M, et al. Renal denervation in an animal model of diabetes and hypertension: impact on the autonomic nervous system and nephropathy. Cardiovasc Diabetol. 2011; 10:33. doi: 10.1186/1475-2840-10-33 PMID: 21496329
9. Doltra A, Messroghli D, Stawowy P, Hassel JH, Gebker R, Leppänen O, et al. Potential reduction of interstitial myocardial fibrosis with renal denervation. J Am Heart Assoc. 2014; 3: e001353. doi: 10.1161/JAHA.114.001353 PMID: 25516438
10. Linz D, van Hunnik A, Hohl M, Mahfoud F, Wolf M, Neuberger HR, et al. Catheter-based renal denervation reduces atrial nerve sprouting and complexity of atrial fibrillation in goats. Circ Arrhythm Electrophysiol. 2015; 8: 466-474. doi: 10.1161/CIRCEP.114.002453 PMID: 25713217
11. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011; 57: 911-917. doi: 10.1161/HYPERTENSIONAHA.110.163014 PMID: 21403086
12. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014; 383: 622-629. doi: 10.1016/S0140-6736(13)62192-3 PMID: 24210779
13. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014; 64: 1071-1078. doi: 10.1016/j.jacc.2014.05.012 PMID: 24858423
14. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012; 126: 2976-2982. doi: 10.1161/CIRCULATIONAHA.112.130880 PMID: 23248063
15. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370: 1393-1401. doi: 10.1056/NEJMoa1402670 PMID: 24678939
16. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011; 91: 265-325. doi: 10.1152/physrev.00031.2009 PMID: 21248168
17. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011; 100: 1049-1057. doi: 10.1007/s00392-011-0335-y PMID: 21688196
18. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-1281. doi: 10.1016/S0140-6736(09)60566-3 PMID: 19332353
19. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011; 58: 559-565. doi: 10.1161/HYPERTENSIONAHA.111.173799 PMID: 21844482
20. Redpath CJ, Rankin AC, Kane KA, Workman AJ. Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic. J Mol Cell Cardiol. 2006; 40: 717-724. PMID: 16603181
21. Booth LC, Malpas SC, Barrett CJ, Guild SJ, Gunn AJ, Bennet L. Renal sympathetic nerve activity during asphyxia in fetal sheep. Am J Physiol Regul Integr Comp Physiol. 2012; 303: R30-8. doi: 10.1152/ajpregu.00063.2012 PMID: 22552793
22. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012; 60: 172-178. doi: 10.1161/HYPERTENSIONAHA.112.191965 PMID: 22585944
23. Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. J Am Coll Cardiol. 2015; 66: 943-959. doi: 10.1016/j.jacc.2015.06.1313 PMID: 26293766
24. Watanabe H, Iwanaga Y, Miyaji Y, Yamamoto H, Miyazaki S. Renal denervation mitigates cardiac remodeling and renal damage in Dahl rats: a comparison with β-receptor blockade. Hypertens Res. 2015; 39: 217-226. doi: 10.1038/hr.2015.133 PMID: 26631854
25. Liang Z, Liu LF, Chen XP, Shi XM, Guo HY, Lin K, et al. Establishment of a Model of Renal Impairment with Mild Renal Insufficiency Associated with Atrial Fibrillation in Canines. PLoS ONE. 2014; 9: e105974. doi: 10.1371/journal.pone.0105974 PMID: 25157494
26. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006; 152: 217-222. PMID: 16875900
27. Lévy S. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation-indications and contraindications. Nat Clin Pract Cardiovasc Med. 2006; 3: 220-225. PMID: 16568131
28. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006; 152: 86-92. PMID: 16838426
29. Patel BM, Mehta AA. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol. 2012; 697: 1-12. doi: 10.1016/j.ejphar.2012.09.034 PMID: 23041273